2024 J.P. Morgan Healthcare Conference: What were the key takeaways?
@Shutterstock

2024 J.P. Morgan Healthcare Conference: What were the key takeaways?

Welcome to the 93 new subscribers who joined our LinkedIn newsletter last week ?? If not done yet, subscribe to join the 5,335 fans of the Pick of the Week!


Did you follow what happened at the J.P. Morgan Healthcare Conference (JPM) a couple of weeks ago?

Well, as thousands gathered at the event, there were a number of key takeaways for the biotech industry, laying the groundwork for what we can expect in 2024.

Some of the key highlights included a buzz around CNS disorders and much talk about the promise of GLP-1 agonists and precision medicine.

But that’s not all.

Plenty more was discussed at JPM 2024, and there was even an air of cautious optimism about the year ahead.

To find out more, read the full article: "2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year "


?? More noteworthy articles from this week:

Although bladder cancer survival rates are relatively high, this type of cancer also has a high chance of resurfacing, emphasizing the importance of finding more effective treatment options.

The hype around GLP-1 agonists has been hard to ignore since the FDA approval of Ozempic in 2017 - but what is it that makes this class of drugs so special in the first place?

While the research around using CRISPR for neurodegenerative diseases is still very much in the early stages, several studies have shown promising results, demonstrating how the gene-editing technology could be used to treat Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The much-awaited Drugs to Watch list by global analytics company Clarivate is out, as we take a closer look at some of the drugs that made it onto the list, having obtained regulatory approval in 2023.

France has a biotech industry that stands at the forefront of global healthcare advancements and is one of the top-performing countries in the industry among the OECD members - we take a look at 19 French biotech companies we think you should know about.


??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.


要查看或添加评论,请登录

社区洞察

其他会员也浏览了